| |||||||||||||||
- Description
- Phenotype
- Genes & alleles
- Genotyping
- Health & husbandry
- References
- Purchasing information
- Terms of Use
Description
Strain Information
Type Congenic; Mutant Strain; Transgenic; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Additional information on Congenic nomenclature. Mating System +/+ sibling x Hemizygote (Female x Male) 25-APR-08 Species laboratory mouse Generation N10F2 (30-DEC-08) Donating Investigator IMR Colony, The Jackson Laboratory Description
Mice that are homozygous for this "MerCreMer" double fusion protein are viable, fertile, normal in size, and do not display any gross physical or behavioral abnormalities. Cre expression in heart tissue is confirmed by western blot. Southern blot confirmed heart cell specificity compared to brain, kidney, lung, liver, and skeletal muscle. Insertion of this transgene and its protein show no changes in echocardiography, heart mass or pathology, or hypertrophy marker genes compared to nontransgenic littermates. Of note, this double fusion protein has substantially greater Cre recombinase activity with less promiscuity compared with a single CreMer fusion protein. As the cre is flanked on each end with a mutated murine estrogen receptor ligand binding domain (amino acids 281-599, G525R); Cre expression is tamoxifen inducible yet estrogen insensitive. Inducible expression of cre in cardiac cells makes this strain suitable for creating bitransgenic mice for use in studies of temporally regulated deletion of loxP-flanked targeted genes.In an attempt to offer alleles on well-characterized or multiple genetic backgrounds, alleles are frequently moved to a genetic background different from that on which an allele was first characterized. It should be noted that the phenotype could vary from that originally described. We will modify the strain description if necessary as published results become available.
Development
A transgenic construct using the cardiac-specific murine alpha-myosin heavy chain promoter to direct expression of a double fusion protein was injected into FVB/N embryos. This double fusion protein, MerCreMer, has Cre recombinase gene flanked on each end with a mutated murine estrogen receptor ligand binding domain (amino acids 281-599, G525R); thus rendering cre expression tamoxifen inducible yet estrogen insensitive. These embryos were implanted into pseudopregnant FVB/N females. Founder animals were backcrossed to mice with a (B6 x 129/Sv)F1 genetic background for 15 generations and were subsequently backcrossed to C57BL/6J mice for 5 generations.
Control Information
| Control | ||
|---|---|---|
| Noncarrier | ||
| Considerations for Choosing Controls | ||
Related Strains
Strains carrying Tg(Myh6-cre/Esr1)1Jmk allele
005650 B6;129-Tg(Myh6-cre/Esr1)1Jmk/J View Strains carrying Tg(Myh6-cre/Esr1)1Jmk (1 strain)
006403 129S.B6-Tg(KRT14-Esr1/HRAS)1Pkha/J 004744 B6.129P2-Esr1tm1Ksk/J 004682 B6.Cg-Tg(CAG-cre/Esr1)5Amc/J 006774 FVB-Tg(Col2a1-cre/ESR1)KA3Smac/J 006822 FVB-Tg(KRT14-MAP2K1/Esr1)12Pkha/J 008464 STOCK Foxa2tm2.1(cre/Esr1)Moon/J 004453 STOCK Tg(CAG-cre/Esr1)5Amc/J 008122 STOCK Tg(Ins2-cre/Esr1)1Dam/J 005107 STOCK Tg(KRT14-cre/Esr1)20Efu/J 008119 STOCK Tg(Neurog3-cre/Esr1)1Dam/J
010587 FVB-Tg(Myh6-MEF2A)1Jmol/J 008716 FVB/N-Tg(Myh6-AIP/PLN*)46Jded/J 009075 STOCK Tg(Myh6-Ppp3ca)37Eno/J 009074 STOCK Tg(Myh6-cre)1Jmk/J
Additional Web Information
Introduction to Cre-lox technology
Phenotype
Phenotype Information
This mouse can be used to support research in many areas including:
cre relatedResearch Tools
Cardiovascular Research
Cre-lox System
Cre-lox System
Cre Recombinase Expression: Inducible
Genetics Research
Mutagenesis and Transgenesis: Cre-lox System
Tissue/Cell Markers: Cre-lox System
Research Tools
Cre-lox System
Genetics Research
Mutagenesis and Transgenesis: Cre-lox System
Genes & Alleles
Gene & Allele Information
| Allele Symbol | Tg(Myh6-cre/Esr1)1Jmk | ||
|---|---|---|---|
| Allele Name | transgene insertion 1, Jeffery D Molkentin | ||
| Allele Type | Transgenic (Cre/Flp) | ||
| Common Name(s) | MCM; MerCreMer; alpha-MHC-MerCreMer; alphaMHC-Cre-Mer-Cre; mer; | ||
| Mutation Made By | Jeffery Molkentin, Children's Hospital Medical Center | ||
| Strain of Origin | FVB | ||
| Site of Expression | tamoxifen inducible (yet estrogen insensitive) Cre recombinase protein fused to two mutant estrogen-receptor ligand-binding domains (MerCreMer); expression in developing and adult heart | ||
| Expressed Gene | cre, cre recombinase, bacteriophage P1 | ||
| Cre recombinase is an enzyme derived from the bacteriophage P1 that specifically recognizes loxP sites. Cre has been shown to effectively mediate the excision of DNA located between loxP sites. After the excision event, the DNA ends recombine leaving a single loxP site in place of the intervening sequence. | |||
| Expressed Gene | Esr1, estrogen receptor 1 (alpha), mouse, laboratory | ||
| Promoter | Myh6, myosin, heavy polypeptide 6, cardiac muscle, alpha, murine, murine | ||
| Driver Note | Myh6 | ||
| Inducible Note | induced by tamoxifen | ||
| Molecular Note | This transgene expresses a cre recombinase/ mutant estrogen receptor ligand binding domain fusion protein under the control of a mouse cardiac-specific alpha-myosin heavy chain promoter. Expression was detected in the juvenile and adult heart, but the protein is inactive until induced with tamoxifen. [MGI Ref ID J:82027] | ||
| Gene Symbol and Name | Tg(Myh6-cre/Esr1)1Jmk, transgene insertion 1, Jeffery D Molkentin | ||
| Chromosome | UN | ||
| Gene Common Name(s) | MCM; MerCreMer; alpha-MHC-MerCreMer; alphaMHC-Cre-Mer-Cre; mer; | ||
Genotyping
Genotyping Information
Genotyping Protocols
Tg(cre/Esr1), Standard PCR
Helpful Links
Genotyping resources and troubleshooting
References
References
Selected Reference(s)
Sohal DS; Nghiem M; Crackower MA; Witt SA; Kimball TR; Tymitz KM; Penninger JM; Molkentin JD. 2001. Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein. Circ Res 89(1):20-5. [PubMed: 11440973] [MGI Ref ID J:82027]
Additional References
Tg(Myh6-cre/Esr1)1Jmk relatedChen X; Shevtsov SP; Hsich E; Cui L; Haq S; Aronovitz M; Kerkela R; Molkentin JD; Liao R; Salomon RN; Patten R; Force T. 2006. The beta-catenin/T-cell factor/lymphocyte enhancer factor signaling pathway is required for normal and stress-induced cardiac hypertrophy. Mol Cell Biol 26(12):4462-73. [PubMed: 16738313] [MGI Ref ID J:109612]
Diwan A; Wansapura J; Syed FM; Matkovich SJ; Lorenz JN; Dorn GW nd. 2008. Nix-mediated apoptosis links myocardial fibrosis, cardiac remodeling, and hypertrophy decompensation. Circulation 117(3):396-404. [PubMed: 18178777] [MGI Ref ID J:145086]
Georges R; Nemer G; Morin M; Lefebvre C; Nemer M. 2008. Distinct expression and function of alternatively spliced Tbx5 isoforms in cell growth and differentiation. Mol Cell Biol 28(12):4052-67. [PubMed: 18391012] [MGI Ref ID J:137268]
Herrmann S; Stieber J; Stockl G; Hofmann F; Ludwig A. 2007. HCN4 provides a 'depolarization reserve' and is not required for heart rate acceleration in mice. EMBO J 26(21):4423-32. [PubMed: 17914461] [MGI Ref ID J:139560]
Ito K; Akazawa H; Tamagawa M; Furukawa K; Ogawa W; Yasuda N; Kudo Y; Liao CH; Yamamoto R; Sato T; Molkentin JD; Kasuga M; Noda T; Nakaya H; Komuro I. 2009. PDK1 coordinates survival pathways and beta-adrenergic response in the heart. Proc Natl Acad Sci U S A 106(21):8689-94. [PubMed: 19429709] [MGI Ref ID J:150014]
Kostetskii I; Li J; Xiong Y; Zhou R; Ferrari VA; Patel VV; Molkentin JD; Radice GL. 2005. Induced deletion of the N-cadherin gene in the heart leads to dissolution of the intercalated disc structure. Circ Res 96(3):346-54. [PubMed: 15662031] [MGI Ref ID J:98828]
Lavine KJ; Kovacs A; Ornitz DM. 2008. Hedgehog signaling is critical for maintenance of the adult coronary vasculature in mice. J Clin Invest 118(7):2404-14. [PubMed: 18568073] [MGI Ref ID J:137685]
Lavine KJ; White AC; Park C; Smith CS; Choi K; Long F; Hui CC; Ornitz DM. 2006. Fibroblast growth factor signals regulate a wave of Hedgehog activation that is essential for coronary vascular development. Genes Dev 20(12):1651-66. [PubMed: 16778080] [MGI Ref ID J:109722]
Li J; Levin MD; Xiong Y; Petrenko N; Patel VV; Radice GL. 2008. N-cadherin haploinsufficiency affects cardiac gap junctions and arrhythmic susceptibility. J Mol Cell Cardiol 44(3):597-606. [PubMed: 18201716] [MGI Ref ID J:133753]
Li J; Patel VV; Kostetskii I; Xiong Y; Chu AF; Jacobson JT; Yu C; Morley GE; Molkentin JD; Radice GL. 2005. Cardiac-specific loss of N-cadherin leads to alteration in connexins with conduction slowing and arrhythmogenesis. Circ Res 97(5):474-81. [PubMed: 16100040] [MGI Ref ID J:112334]
Lisewski U; Shi Y; Wrackmeyer U; Fischer R; Chen C; Schirdewan A; Juttner R; Rathjen F; Poller W; Radke MH; Gotthardt M. 2008. The tight junction protein CAR regulates cardiac conduction and cell-cell communication. J Exp Med 205(10):2369-79. [PubMed: 18794341] [MGI Ref ID J:140109]
Moga MA; Nakamura T; Robbins J. 2008. Genetic approaches for changing the heart and dissecting complex syndromes. J Mol Cell Cardiol 45(2):148-55. [PubMed: 18601931] [MGI Ref ID J:139282]
Moshal KS; Kumar M; Tyagi N; Mishra PK; Metreveli N; Rodriguez WE; Tyagi SC. 2009. Restoration of contractility in hyperhomocysteinemia by cardiac-specific deletion of NMDA-R1. Am J Physiol Heart Circ Physiol 296(3):H887-92. [PubMed: 19181966] [MGI Ref ID J:146860]
Nakai A; Yamaguchi O; Takeda T; Higuchi Y; Hikoso S; Taniike M; Omiya S; Mizote I; Matsumura Y; Asahi M; Nishida K; Hori M; Mizushima N; Otsu K. 2007. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat Med 13(5):619-24. [PubMed: 17450150] [MGI Ref ID J:121778]
Parlakian A; Charvet C; Escoubet B; Mericskay M; Molkentin JD; Gary-Bobo G; De Windt LJ; Ludosky MA; Paulin D; Daegelen D; Tuil D; Li Z. 2005. Temporally controlled onset of dilated cardiomyopathy through disruption of the SRF gene in adult heart. Circulation 112(19):2930-9. [PubMed: 16260633] [MGI Ref ID J:135043]
Peng J; Raddatz K; Molkentin JD; Wu Y; Labeit S; Granzier H; Gotthardt M. 2007. Cardiac hypertrophy and reduced contractility in hearts deficient in the titin kinase region. Circulation 115(6):743-51. [PubMed: 17261657] [MGI Ref ID J:132331]
Petrich BG; Molkentin JD; Wang Y. 2003. Temporal activation of c-Jun N-terminal kinase in adult transgenic heart via cre-loxP-mediated DNA recombination. FASEB J 17(6):749-51. [PubMed: 12594183] [MGI Ref ID J:128410]
Raake PW; Vinge LE; Gao E; Boucher M; Rengo G; Chen X; DeGeorge BR Jr; Matkovich S; Houser SR; Most P; Eckhart AD; Dorn GW nd; Koch WJ. 2008. G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ Res 103(4):413-22. [PubMed: 18635825] [MGI Ref ID J:152649]
Ruan H; Mitchell S; Vainoriene M; Lou Q; Xie LH; Ren S; Goldhaber JI; Wang Y. 2007. Gi alpha 1-mediated cardiac electrophysiological remodeling and arrhythmia in hypertrophic cardiomyopathy. Circulation 116(6):596-605. [PubMed: 17646583] [MGI Ref ID J:139853]
Sano M; Minamino T; Toko H; Miyauchi H; Orimo M; Qin Y; Akazawa H; Tateno K; Kayama Y; Harada M; Shimizu I; Asahara T; Hamada H; Tomita S; Molkentin JD; Zou Y; Komuro I. 2007. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 446(7134):444-8. [PubMed: 17334357] [MGI Ref ID J:120332]
Syed F; Odley A; Hahn HS; Brunskill EW; Lynch RA; Marreez Y; Sanbe A; Robbins J; Dorn GW nd. 2004. Physiological growth synergizes with pathological genes in experimental cardiomyopathy. Circ Res 95(12):1200-6. [PubMed: 15539635] [MGI Ref ID J:133068]
Wang D; Patel VV; Ricciotti E; Zhou R; Levin MD; Gao E; Yu Z; Ferrari VA; Lu MM; Xu J; Zhang H; Hui Y; Cheng Y; Petrenko N; Yu Y; FitzGerald GA. 2009. Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function. Proc Natl Acad Sci U S A 106(18):7548-52. [PubMed: 19376970] [MGI Ref ID J:148331]
Wang GS; Kearney DL; De Biasi M; Taffet G; Cooper TA. 2007. Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy. J Clin Invest 117(10):2802-11. [PubMed: 17823658] [MGI Ref ID J:127391]
Xiao R; Sun Y; Ding JH; Lin S; Rose DW; Rosenfeld MG; Fu XD; Li X. 2007. Splicing regulator SC35 is essential for genomic stability and cell proliferation during mammalian organogenesis. Mol Cell Biol 27(15):5393-402. [PubMed: 17526736] [MGI Ref ID J:123618]
Xiong D; Yajima T; Lim BK; Stenbit A; Dublin A; Dalton ND; Summers-Torres D; Molkentin JD; Duplain H; Wessely R; Chen J; Knowlton KU. 2007. Inducible cardiac-restricted expression of enteroviral protease 2A is sufficient to induce dilated cardiomyopathy. Circulation 115(1):94-102. [PubMed: 17190866] [MGI Ref ID J:128060]
Yoshioka J; Imahashi K; Gabel SA; Chutkow WA; Burds AA; Gannon J; Schulze PC; MacGillivray C; London RE; Murphy E; Lee RT. 2007. Targeted deletion of thioredoxin-interacting protein regulates cardiac dysfunction in response to pressure overload. Circ Res 101(12):1328-38. [PubMed: 17916779] [MGI Ref ID J:141487]
Zheng M; Cheng H; Li X; Zhang J; Cui L; Ouyang K; Han L; Zhao T; Gu Y; Dalton ND; Bang ML; Peterson KL; Chen J. 2009. Cardiac-specific ablation of Cypher leads to a severe form of dilated cardiomyopathy with premature death. Hum Mol Genet 18(4):701-13. [PubMed: 19028670] [MGI Ref ID J:144739]
Zhong W; Mao S; Tobis S; Angelis E; Jordan MC; Roos KP; Fishbein MC; de Alboran IM; MacLellan WR. 2006. Hypertrophic growth in cardiac myocytes is mediated by Myc through a Cyclin D2-dependent pathway. EMBO J 25(16):3869-79. [PubMed: 16902412] [MGI Ref ID J:119290]
Zhou J; Qu J; Yi XP; Graber K; Huber L; Wang X; Gerdes AM; Li F. 2007. Upregulation of gamma-catenin compensates for the loss of beta-catenin in adult cardiomyocytes. Am J Physiol Heart Circ Physiol 292(1):H270-6. [PubMed: 16936006] [MGI Ref ID J:119968]
Health & husbandry
Health & Colony Maintenance Information
Animal Health Reports
Room Number AX12
Colony Maintenance
Breeding & Husbandry Current colony is maintained by hemizygote X wildtype sibling (or reciprocal) crosses. Mating System +/+ sibling x Hemizygote (Female x Male) 25-APR-08 Diet Information LabDiet® 5K52/5K67
Purchasing information
Pricing, Supply Level & Notes, Controls, General Terms & Conditions
Pricing
| Pricing for USA, Canada and Mexico shipping destinations |
|
Weeks of Age Price (US dollars $) Gender Genotypes Provided Individual Mouse $243.50 Female or Male Hemizygous for Tg(Myh6-cre/Esr1)1Jmk
Pairs /Price (US dollars $) Pair Genotype $297.85 Hemizygous for Tg(Myh6-cre/Esr1)1Jmk x Noncarrier $297.85 Noncarrier x Hemizygous for Tg(Myh6-cre/Esr1)1Jmk
Additional Supply Details
| Pricing for International shipping destinations |
|
Weeks of Age Price (US dollars $) Gender Genotypes Provided Individual Mouse $316.60 Female or Male Hemizygous for Tg(Myh6-cre/Esr1)1Jmk
Pairs /Price (US dollars $) Pair Genotype $387.30 Hemizygous for Tg(Myh6-cre/Esr1)1Jmk x Noncarrier $387.30 Noncarrier x Hemizygous for Tg(Myh6-cre/Esr1)1Jmk
Additional Supply Details
|
|
|
Supply Details
| Standard Supply | Repository-Live. A collection of over 1000 strains maintained as live colonies. Individual colonies are sized to meet current customer demand. Delivery for orders of 10 mice or less ranges on average from one to eight weeks; mice are generally shipped between four to six weeks of age with a maximum shipping age of approximately nine weeks. Colony sizes do not generally support stringent age specifications for large volumes of mice; however custom orders and larger quantities of mice are easily arranged. Estimated ship dates for all orders provided within two business days following order placement. |
|---|---|
| Supply Notes |
|
Control Information
| Control | ||
|---|---|---|
| Noncarrier | ||
| Considerations for Choosing Controls | ||
| USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
| International - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
Payment Terms and Conditions
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
See Terms of Use tab for General Terms and Conditions
The Jackson Laboratory's Genotype Promise
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.Ordering and Purchasing Information
Purchasing Information
JAX® Mice Orders
Surgical Services
Contact Information
Orders & Technical Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form
Terms of Use
Terms of Use
General Terms and Conditions
For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
Contact information
General inquiries
Contracts Administration
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
JAX® Mice, Products & Services Conditions of Use
"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.No Warranty
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
No Liability
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. In purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.